Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q2 2026: AstraZeneca 15.384, CSL 3.6525.
* CSL reports semi-annually. Values are evenly split across both quarters within each half.
AstraZeneca vs CSL: Revenue Comparison
AstraZeneca (AZN) and CSL (CSL.AX) are peers in Vaccines. AstraZeneca reported revenue of $15.4B as of Q2 2026, compared with $7.3B for CSL. AstraZeneca leads on revenue.
AstraZeneca's gross margin is 83.6% versus 44.4% for CSL. AstraZeneca's net margin is 16.3% versus -40.2% for CSL.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, AstraZeneca, CSL.| Metric | AstraZeneca | CSL |
|---|---|---|
| Market Cap | - | - |
| Revenue | $15.38B | $7.30B |
| Cost of Revenue | $2.52B | $4.06B |
| Gross Profit | $12.86B | $3.24B |
| Operating Income | $3.16B | $1.39B |
| Net Income | $2.51B | $-2.94B |
| R&D Expense | $4.05B | $614.00M |
| Earnings Per Share | $1.59 | -$6.14 |
| Gross Margin | 83.6% | 44.4% |
| Operating Margin | 20.6% | 19.0% |
| Net Profit Margin | 16.3% | -40.2% |
| Free Cash Flow | $2.13B | $1.76B |
| Cumulative Free Cash Flow | $121.22B | $21.56B |
| Operating Cash Flow | $2.89B | $2.09B |
| Cash & Equivalents | $4.89B | $1.51B |